Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Enhancement of Cetuximab-Induced Antibody-Dependent Cellular Cytotoxicity (ADCC) With Lenalidomide in Advanced Solid Tumors: A Phase I/IB Study

NCT01254617 is registered in ClinicalTrials.gov with National Cancer Institute (NCI) as lead sponsor.

NCT NCT01254617
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01254617 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Enhancement of Cetuximab-Induced Antibody-Dependent Cellular Cytotoxicity (ADCC) With Lenalidomide in Advanced Solid Tumors: A Phase I/IB Study
Lead sponsor
National Cancer Institute (NCI)
Phase
Phase 1
Overall status
Completed
Start date
February 10, 2011
Completion date
January 29, 2014
Enrollment
24 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

recurrent colon carcinoma, recurrent hypopharyngeal squamous cell carcinoma, recurrent laryngeal squamous cell carcinoma, recurrent laryngeal verrucous carcinoma, recurrent lip and oral cavity squamous cell carcinoma, recurrent metastatic squamous cell carcinoma in the neck with occult primary, recurrent nasal cavity and paranasal sinus squamous cell carcinoma, recurrent nasopharyngeal keratinizing squamous cell carcinoma, recurrent oral cavity verrucous carcinoma, recurrent oropharyngeal squamous cell carcinoma, recurrent rectal carcinoma, recurrent salivary gland carcinoma, salivary gland squamous cell carcinoma, squamous cell carcinoma metastatic in the neck with occult primary, stage iv hypopharyngeal squamous cell carcinoma ajcc v7, stage iv nasopharyngeal keratinizing squamous cell carcinoma ajcc v7, stage iva colon cancer ajcc v7, stage iva laryngeal squamous cell carcinoma ajcc v7, stage iva laryngeal verrucous carcinoma ajcc v7, stage iva lip and oral cavity squamous cell carcinoma ajcc v6 and v7, stage iva major salivary gland cancer ajcc v7, stage iva nasal cavity and paranasal sinus squamous cell carcinoma ajcc v7, stage iva oral cavity cancer ajcc v6 and v7, stage iva oropharyngeal squamous cell carcinoma ajcc v7, stage iva rectal cancer ajcc v7, stage ivb colon cancer ajcc v7, stage ivb laryngeal squamous cell carcinoma ajcc v7, stage ivb laryngeal verrucous carcinoma ajcc v7, stage ivb lip and oral cavity squamous cell carcinoma ajcc v6 and v7, stage ivb major salivary gland cancer ajcc v7, stage ivb nasal cavity and paranasal sinus squamous cell carcinoma ajcc v7, stage ivb oral cavity cancer ajcc v6 and v7, stage ivb oropharyngeal squamous cell carcinoma ajcc v7, stage ivb rectal cancer ajcc v7, stage ivc laryngeal squamous cell carcinoma ajcc v7, stage ivc laryngeal verrucous carcinoma ajcc v7, stage ivc lip and oral cavity squamous cell carcinoma ajcc v6 and v7, stage ivc major salivary gland cancer ajcc v7, stage ivc nasal cavity and paranasal sinus squamous cell carcinoma ajcc v7, stage ivc oral cavity cancer ajcc v6 and v7, stage ivc oropharyngeal squamous cell carcinoma ajcc v7, tongue carcinoma